INTEGRATE II
14 Dec 2020
INTEGRATE II
ACTRN12616000420448
A Randomised Phase III Double-Blind Placebo-Controlled Study of regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
The Australasian Gastro-Intestinal Trials Group (AGITG)
Cancer Type | Stomach & Oesophageal |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
Anticipated Start Date | 2016-11-01 |
Anticipated End Date | 2021-12-01 |
Hospital | Flinders Medical Centre |
---|---|
Clinical Trial Coordinator | Alex Scott-Hoy |
alex.scott-hoy@sa.gov.au | |
Phone | 08 8204 4830 |
Principal Investigator | Professor Chris Karapetis |
Recruitment Status | Recruiting |
Hospital | The Queen Elizabeth Hospital |
---|---|
Clinical Trial Coordinator | Pamela Cooper |
pamela.cooper@sa.gov.au | |
Phone | 08 8222 6140 |
Principal Investigator | Professor Tim Price |
Recruitment Status | Recruiting |
Hospital | Ashford Cancer Centre Research |
---|---|
Clinical Trial Coordinator | Sue Yeend |
syeend@adelaidecancercentre.com.au | |
Phone | 08 8292 2240 |
Principal Investigator | Dr Caroline Bampton |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs